JM Mid cap Fund
The scheme seeks to provide long-term capital appreciation/income by investing predominantly in Mid-Cap companies. There is no assurance that the investment objective of the Scheme will be realized.
Growthvine rating: 3/5 — ranked #10 of 34 in category.
Fund basics
| Category | Equity: Mid Cap |
|---|
| NAV | ₹20.10 (as of 2026-10-16) |
|---|
| AUM | ₹1,303 Cr |
|---|
| Expense ratio | 1.85% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Satish Ramanathan |
|---|
| Exit load | 1% for redemption within 180 days |
|---|
Performance & risk
| Sharpe ratio | 0.58 |
|---|
| Standard deviation | 19.30% |
|---|
| Max drawdown | −23.08% |
|---|
| Alpha | 2.33 |
|---|
| Beta | 1 |
|---|
Over 5 years, captured 104.0% of NIFTY Midcap 150's upside and 92.0% of its downside.
Market cap allocation
| Large cap | 5.0% |
|---|
| Mid cap | 68.7% |
|---|
| Small cap | 26.3% |
|---|
Concentration
| Top 5 holdings | 15.3% |
|---|
| Top 10 holdings | 28.1% |
|---|
| Total holdings | 72 |
|---|
| Index overlap | 34.6% |
|---|
| Active share | 65.4% |
|---|
Top holdings
- One 97 Communications Limited — 3.6%
- Avalon Technologies Limited — 3.1%
- Mankind Pharma Limited — 2.9%
- Godfrey Phillips India Ltd. — 2.9%
- IDFC FIRST BANK LIMITED — 2.8%
- Bank of maharashtra — 2.8%
- Marico Limited — 2.7%
- Glenmark Pharmaceuticals ltd — 2.7%
- Sona BLW Precision Forgings Limited — 2.4%
- ACUTAAS CHEMICALS LIMITED — 2.3%
Top sectors
- Banking & Financial — 16.6%
- Pharma & Biotech — 12.4%
- Automobile — 11.1%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 5.8% | Q1 (Top) | #3 of 31 |
| 2025 | −2.7% | Q4 (Bottom) | #26 of 29 |
| 2024 | 35.3% | Q1 (Top) | #5 of 29 |
| 2023 | 44.5% | Q1 (Top) | #3 of 28 |